Limits...
Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.

Huang W, Zhang W, Fan M, Lu Y, Zhang J, Li H, Li B - Cancer Sci. (2014)

Bottom Line: The HBV DNA level and dose volume parameters including normal liver volume, V20, and mean dose were associated with HBV reactivation.There was a relatively high incidence of HBV reactivation in HCC patients after the end of conformal RT.The serum HBV DNA level and some dosimetric parameters related to normal liver, including normal liver volume, V20, and mean dose, were the prognosis factors of HBV reactivation and should be carefully considered before conformal RT.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology VI, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Shandong's Key Laboratory of Radiation Oncology, Jinan, China.

Show MeSH

Related in: MedlinePlus

Cumulative rates of radiation-induced liver disease (RILD), hepatitis B virus (HBV) reactivation and HBV reactivation-induced hepatitis in patients with hepatocellular carcinoma (n = 69).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317906&req=5

fig02: Cumulative rates of radiation-induced liver disease (RILD), hepatitis B virus (HBV) reactivation and HBV reactivation-induced hepatitis in patients with hepatocellular carcinoma (n = 69).

Mentions: The RILD incidence rate was 17.4% (12/69), with 10.1% (7/69) diagnosed as classic RILD and 7.3% (5/69) as non-classic RILD. The peak probability of RILD happened at 8 weeks after the end of RT, which was 7.2% (5/69). The cumulative RILD rates at 4, 8, 12, and 16 weeks after the end of RT were 4.3% (3/69), 11.6% (8/69), 15.9% (11/69), and 17.4% (12/69), respectively (Fig.2). Of 12 RILD patients, protection of liver function was efficient in seven patients who lived up to the follow-up endpoint, but was inefficient in five patients who died of liver function failure 4 months after the end of RT.


Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.

Huang W, Zhang W, Fan M, Lu Y, Zhang J, Li H, Li B - Cancer Sci. (2014)

Cumulative rates of radiation-induced liver disease (RILD), hepatitis B virus (HBV) reactivation and HBV reactivation-induced hepatitis in patients with hepatocellular carcinoma (n = 69).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317906&req=5

fig02: Cumulative rates of radiation-induced liver disease (RILD), hepatitis B virus (HBV) reactivation and HBV reactivation-induced hepatitis in patients with hepatocellular carcinoma (n = 69).
Mentions: The RILD incidence rate was 17.4% (12/69), with 10.1% (7/69) diagnosed as classic RILD and 7.3% (5/69) as non-classic RILD. The peak probability of RILD happened at 8 weeks after the end of RT, which was 7.2% (5/69). The cumulative RILD rates at 4, 8, 12, and 16 weeks after the end of RT were 4.3% (3/69), 11.6% (8/69), 15.9% (11/69), and 17.4% (12/69), respectively (Fig.2). Of 12 RILD patients, protection of liver function was efficient in seven patients who lived up to the follow-up endpoint, but was inefficient in five patients who died of liver function failure 4 months after the end of RT.

Bottom Line: The HBV DNA level and dose volume parameters including normal liver volume, V20, and mean dose were associated with HBV reactivation.There was a relatively high incidence of HBV reactivation in HCC patients after the end of conformal RT.The serum HBV DNA level and some dosimetric parameters related to normal liver, including normal liver volume, V20, and mean dose, were the prognosis factors of HBV reactivation and should be carefully considered before conformal RT.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology VI, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Shandong's Key Laboratory of Radiation Oncology, Jinan, China.

Show MeSH
Related in: MedlinePlus